NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma

about

Targeted next-generation sequencing of cancer genes in poorly differentiated thyroid cancer.TERT promoter hotspot mutations in breast cancer.

P2860

Q47150624-65BC9721-BBC9-482F-BE1E-FFC8451118C8 Q47339267-334DADA6-A18C-4817-8B8E-F22F1D35DC49

P2860

NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma

Item

http://www.wikidata.org/entity/Q42014310

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

NGS based identification of mu ...... n anaplastic thyroid carcinoma

@en

NGS based identification of mu ...... n anaplastic thyroid carcinoma

@nl

type

Item

label

NGS based identification of mu ...... n anaplastic thyroid carcinoma

@en

NGS based identification of mu ...... n anaplastic thyroid carcinoma

@nl

prefLabel

NGS based identification of mu ...... n anaplastic thyroid carcinoma

@en

NGS based identification of mu ...... n anaplastic thyroid carcinoma

@nl

P1476

NGS based identification of mu ...... n anaplastic thyroid carcinoma

@en

P2093

Dagmar Fuehrer

http://www.w3.org/2001/XMLSchema#string

Denise Zwanziger

http://www.w3.org/2001/XMLSchema#string

Kurt Werner Schmid

http://www.w3.org/2001/XMLSchema#string

Martin Stuschke

http://www.w3.org/2001/XMLSchema#string

Sarah Synoracki

http://www.w3.org/2001/XMLSchema#string

Soeren Latteyer

http://www.w3.org/2001/XMLSchema#string

Thomas Herold

http://www.w3.org/2001/XMLSchema#string

Vera Tiedje

http://www.w3.org/2001/XMLSchema#string

P2860

Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene

Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence

Response and acquired resistance to everolimus in anaplastic thyroid cancer

Integrated genomic characterization of papillary thyroid carcinoma

The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations

A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.

The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.

Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility.

P304

42613-42620

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.17300

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Lars C Moeller

S Ting

P577

2017-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28489587

http://www.w3.org/2001/XMLSchema#string

P932

5522092

http://www.w3.org/2001/XMLSchema#string

NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma

about

P2860

P2860

NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932